Genetically engineered patient T cells with chimeric T cell receptors (CAR T cells) can induce anti-tumour responses, but such responses are determined by the variable capacity of the CAR T cells to expand and persist in patients. Here the authors report on a case of a chronic lymphocytic leukaemia patient treated with CD19 CAR T cells that resulted in complete remission. Unexpectedly, CAR T cells showed expansion of a clone where insertion of the CAR transgene disrupted the endogenous TET2 gene. In addition, the remaining allele was shown to carry a hypomorphic mutation. The resulting inactivation of this methylcytosine dioxygenase induced epigenetic changes that altered T cell differentiation and function, promoting a central memory phenotype and potentiating anti-tumour effects. This finding suggests that modulating TET2 signalling could improve the efficacy of CAR T cells.
- Tumour tamed by transfer of one T cell (News & Views p193, doi: 10.1038/d41586-018-05251-5)
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells (Letter p307, doi: 10.1038/s41586-018-0178-z)
Recent Hot Topics
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.